

# Phosphorylated SMAD2 and SMAD3 form a complex with SMAD4

Chen, YG., Contreras, O., Heldin, CH., Huang, T., Huminiecki, L., Jassal, B., Moustakas, A., Orlic-Milacic, M.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

16/05/2024

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

## Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

## Phosphorylated SMAD2 and SMAD3 form a complex with SMAD4 ↗

**Stable identifier:** R-HSA-170847

**Type:** transition

**Compartments:** cytosol



The phosphorylated C-terminal tail of R-SMAD induces a conformational change in the MH2 domain (Qin et al. 2001, Chacko et al. 2004), which now acquires high affinity towards Co-SMAD i.e. SMAD4 (common mediator of signal transduction in TGF-beta/BMP signaling). The R-SMAD:Co-SMAD complex (Nakao et al. 1997) most likely is a trimer of two R-SMADs with one Co-SMAD (Kawabata et al. 1998). It is important to note that the Co-SMAD itself cannot be phosphorylated as it lacks the C-terminal serine motif.

ZFYVE16 (endofin) promotes SMAD heterotrimer formation. ZFYVE16 can bind TGFBR1 and facilitate SMAD2 phosphorylation, and it can also bind SMAD4, but the exact mechanism of ZFYVE16 (endofin) action in the context of TGF-beta receptor signaling is not known (Chen et al. 2007).

SARS-CoV-1 nucleocapsid protein (N) associates with SMAD3 and this binding interferes with the complex formation between SMAD3 and SMAD4. By this mechanism N modulates TGF-beta signaling to block apoptosis of SARS-CoV-infected host cells (Zhao et al. 2008).

### Literature references

- Lin, K., Correia, JJ., Chacko, BM., Lam, SS., Qin, BY., de Caestecker, MP. (2001). Structural basis of Smad1 activation by receptor kinase phosphorylation. *Mol Cell*, 8, 1303-12. ↗
- Miyazono, K., Inoue, H., Kawabata, M., Imamura, T., Hanyu, A. (1998). Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. *EMBO J*, 17, 4056-65. ↗
- Wang, Z., Chen, YG., Lu, Z., Zhang, L., Ma, J. (2007). Endofin, a FYVE domain protein, interacts with Smad4 and facilitates transforming growth factor-beta signaling. *J. Biol. Chem.*, 282, 9688-95. ↗
- Shi, G., De Caestecker, M., Lin, K., Chacko, BM., Hayward, LJ., Tiwari, A. et al. (2004). Structural basis of heteromeric smad protein assembly in TGF-beta signaling. *Mol Cell*, 15, 813-23. ↗
- Kyin, S., Rigotti, DJ., Shi, Y., Massague, J., Muir, TW., Li, C. et al. (2001). Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. *Mol Cell*, 8, 1277-89. ↗

Editions

2006-01-18	Edited	Jassal, B.
2006-02-02	Authored	Jassal, B., Heldin, CH., Moustakas, A., Huminiecki, L.
2006-04-18	Reviewed	Heldin, CH.
2012-04-04	Revised	Orlic-Milacic, M.
2012-04-10	Edited	Jassal, B.
2012-05-14	Reviewed	Huang, T.
2012-11-14	Reviewed	Chen, YG.
2013-02-05	Revised	Orlic-Milacic, M.
2022-05-02	Reviewed	Contreras, O.
2022-05-09	Edited	Orlic-Milacic, M.